Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
123.29
+4.16 (3.49%)
At close: Nov 20, 2024, 4:00 PM
124.01
+0.72 (0.58%)
Pre-market: Nov 21, 2024, 4:13 AM EST
Neurocrine Biosciences Employees
Neurocrine Biosciences had 1,400 employees as of December 31, 2023. The number of employees increased by 200 or 16.67% compared to the previous year.
Employees
1,400
Change (1Y)
200
Growth (1Y)
16.67%
Revenue / Employee
$1,602,000
Profits / Employee
$275,643
Market Cap
12.48B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,400 | 200 | 16.67% |
Dec 31, 2022 | 1,200 | 300 | 33.33% |
Dec 31, 2021 | 900 | 55 | 6.51% |
Dec 31, 2020 | 845 | 145 | 20.71% |
Dec 31, 2019 | 700 | 115 | 19.66% |
Dec 31, 2018 | 585 | 185 | 46.25% |
Dec 31, 2017 | 400 | 204 | 104.08% |
Dec 31, 2016 | 196 | 76 | 63.33% |
Dec 31, 2015 | 120 | 26 | 27.66% |
Dec 31, 2014 | 94 | 13 | 16.05% |
Dec 31, 2013 | 81 | 3 | 3.85% |
Dec 31, 2012 | 78 | 7 | 9.86% |
Dec 31, 2011 | 71 | 5 | 7.58% |
Dec 31, 2010 | 66 | 1 | 1.54% |
Dec 31, 2009 | 65 | -60 | -48.00% |
Dec 31, 2008 | 125 | -10 | -7.41% |
Dec 31, 2007 | 135 | -132 | -49.44% |
Dec 31, 2006 | 267 | -321 | -54.59% |
Dec 31, 2005 | 588 | 203 | 52.73% |
Dec 31, 2004 | 385 | 40 | 11.59% |
Dec 31, 2003 | 345 | 69 | 25.00% |
Dec 31, 2002 | 276 | 54 | 24.32% |
Dec 31, 2001 | 222 | 34 | 18.09% |
Dec 31, 2000 | 188 | 37 | 24.50% |
Dec 31, 1999 | 151 | 2 | 1.34% |
Dec 31, 1998 | 149 | 41 | 37.96% |
Dec 31, 1997 | 108 | 5 | 4.85% |
Dec 31, 1996 | 103 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Fresenius Medical Care AG | 119,845 |
Universal Health Services | 96,700 |
DaVita | 70,000 |
Dr. Reddy's Laboratories | 27,048 |
Solventum | 20,098 |
AptarGroup | 13,800 |
Globus Medical | 5,000 |
BioMarin Pharmaceutical | 3,401 |
NBIX News
- 12 days ago - Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels - Seeking Alpha
- 14 days ago - Neurocrine Biosciences Presents New KINECT®-HD Data Showing Consistent Efficacy Across 19 Subgroups and Improvements in Aspects of Emotional Health With INGREZZA® (valbenazine) Capsules - PRNewsWire
- 15 days ago - Neurocrine Biosciences to Participate at Investor Conferences in November - PRNewsWire
- 17 days ago - Neurocrine Biosciences Presents Breadth of Data Demonstrating Holistic Improvements Over Time in Patients With Tardive Dyskinesia Following Treatment With INGREZZA® (valbenazine) Capsules - PRNewsWire
- 17 days ago - Neurocrine Biosciences Presents New Data on INGREZZA® (valbenazine) Capsules at Psych Congress 2024: Majority of Long-Term Study Participants Achieved Remission of Tardive Dyskinesia - PRNewsWire
- 21 days ago - Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Neurocrine Biosciences Reports Third Quarter 2024 Financial Results and Raises 2024 INGREZZA Sales Guidance - PRNewsWire
- 6 weeks ago - Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade) - Seeking Alpha